Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has earned a consensus rating of “Hold” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $33.60.

STRO has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. HC Wainwright boosted their price target on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. Wall Street Zen downgraded shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Wedbush reiterated a “neutral” rating and issued a $100.00 target price (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd.

Sutro Biopharma Stock Performance

Shares of STRO stock opened at $11.57 on Friday. The company has a market capitalization of $98.46 million, a PE ratio of -0.44 and a beta of 1.52. Sutro Biopharma has a 52-week low of $5.23 and a 52-week high of $21.50. The business’s fifty day moving average is $9.60 and its 200 day moving average is $8.93.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.25). Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%.The business had revenue of $9.69 million for the quarter, compared to analysts’ expectations of $10.14 million. On average, sell-side analysts forecast that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Insider Activity

In other news, Director Connie Matsui acquired 5,000 shares of Sutro Biopharma stock in a transaction dated Wednesday, October 15th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $40,000.00. Following the transaction, the director owned 5,000 shares of the company’s stock, valued at $40,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders bought 11,175 shares of company stock valued at $89,598. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Sutro Biopharma

A number of hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC lifted its holdings in shares of Sutro Biopharma by 78.9% in the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company’s stock worth $2,037,000 after acquiring an additional 1,382,661 shares during the last quarter. Nuveen LLC purchased a new position in Sutro Biopharma in the 1st quarter worth $189,000. Velan Capital Investment Management LP lifted its stake in Sutro Biopharma by 197.1% in the second quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company’s stock worth $2,185,000 after purchasing an additional 2,030,000 shares during the last quarter. RBF Capital LLC bought a new stake in Sutro Biopharma in the second quarter worth $114,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Sutro Biopharma during the second quarter valued at about $48,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.